KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Intangibles: 2020-2024

Historic Intangibles for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to $335.9 million.

  • Recursion Pharmaceuticals' Intangibles rose 845.48% to $322.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $322.3 million, marking a year-over-year increase of 845.48%. This contributed to the annual value of $335.9 million for FY2024, which is 821.59% up from last year.
  • Recursion Pharmaceuticals' Intangibles amounted to $335.9 million in FY2024, which was up 821.59% from $36.4 million recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' Intangibles ranged from a high of $335.9 million in FY2024 and a low of $1.3 million during FY2022.
  • Its 3-year average for Intangibles is $124.5 million, with a median of $36.4 million in 2023.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Intangibles dropped by 18.00% in 2021, and later soared by 2,690.43% in 2023.
  • Yearly analysis of 5 years shows Recursion Pharmaceuticals' Intangibles stood at $1.7 million in 2020, then dropped by 18.00% to $1.4 million in 2021, then dropped by 5.70% to $1.3 million in 2022, then soared by 2,690.43% to $36.4 million in 2023, then skyrocketed by 821.59% to $335.9 million in 2024.